Female fertility preservation Innovations and questions
Preserving the potential of becoming genetic mother should now be part of the management of infants, adolescents, and young women at risk for infertility from benign or malignant diseases.
René Frydman, M.D., Ph.D., Michaël Grynberg, M.D., Ph.D.
Volume 105, Issue 1, Pages 4-5
Oocyte and ovarian tissue cryopreservation represents one of the most important advances in the field of reproductive medicine and biology. Preserving a woman’s potential for becoming a genetic mother is now possible for numerous diseases that could impair female fertility either by themselves or as a result of their treatment. However, female fertility preservation is still at the pioneering level and is thus often considered an experimental treatment either from a technical standpoint or in the clinical situation in which it is discussed. As a consequence, many ethics issues are raised with fertility preservation treatment in infants, adolescents, and young women.